266 related articles for article (PubMed ID: 28001303)
21. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
[TBL] [Abstract][Full Text] [Related]
22. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
[TBL] [Abstract][Full Text] [Related]
23. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
25. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
[TBL] [Abstract][Full Text] [Related]
26. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
27. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A
Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578
[TBL] [Abstract][Full Text] [Related]
28. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
[TBL] [Abstract][Full Text] [Related]
29. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning.
Pan X; Levin-Epstein R; Huang J; Ruan D; King CR; Kishan AU; Steinberg ML; Qi XS
Radiother Oncol; 2020 Jul; 148():181-188. PubMed ID: 32388444
[TBL] [Abstract][Full Text] [Related]
30. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
Baker BR; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Jul; 122(14):2234-41. PubMed ID: 27171855
[TBL] [Abstract][Full Text] [Related]
31. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231
[TBL] [Abstract][Full Text] [Related]
32. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.
Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR
Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
Jackson WC; Silva J; Hartman HE; Dess RT; Kishan AU; Beeler WH; Gharzai LA; Jaworski EM; Mehra R; Hearn JWD; Morgan TM; Salami SS; Cooperberg MR; Mahal BA; Soni PD; Kaffenberger S; Nguyen PL; Desai N; Feng FY; Zumsteg ZS; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):778-789. PubMed ID: 30959121
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW; Blacksburg S; Mendez C; Repka M; Sanchez A; Carpenter T; Witten M; Garbus JE; Evans A; Collins SP; Katz A; Haas J
Radiat Oncol; 2021 Jul; 16(1):126. PubMed ID: 34243797
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Koneru H; Cyr R; Feng LR; Bae E; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Saligan L; Simeng S; Kumar D; Collins SP
Cureus; 2016 Jul; 8(7):e669. PubMed ID: 27551649
[TBL] [Abstract][Full Text] [Related]
36. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
Front Oncol; 2016; 6():122. PubMed ID: 27242962
[TBL] [Abstract][Full Text] [Related]
37. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
38. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
Hamstra DA; Conlon AS; Daignault S; Dunn RL; Sandler HM; Hembroff AL; Zietman AL; Kaplan I; Ciezki J; Kuban DA; Wei JT; Sanda MG; Michalski JM;
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):546-53. PubMed ID: 23561651
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP
Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994
[TBL] [Abstract][Full Text] [Related]
40. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2016; 6():114. PubMed ID: 27200300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
